Peds Fasting Duration Not Tied to Adverse Sedation Outcomes

Share this content:
Peds Fasting Duration Not Tied to Adverse Sedation Outcomes
Peds Fasting Duration Not Tied to Adverse Sedation Outcomes

WEDNESDAY, May 9, 2018 (HealthDay News) -- For children undergoing procedural sedation for a painful procedure, fasting duration is not associated with adverse events, according to a study published online May 7 in JAMA Pediatrics.

Maala Bhatt, M.D., from the Children's Hospital of Eastern Ontario in Ottawa, Canada, and colleagues conducted a planned secondary analysis of a prospective cohort study involving children aged 0 to 18 years who received procedural sedation for a painful procedure in six pediatric emergency departments. A total of 6,183 children were included in the analysis; of these, 48.1 and 5 percent did not meet American Society of Anesthesiologists fasting guidelines for solids and liquids, respectively.

The researchers found that there were no cases of pulmonary aspiration. A total of 717 adverse events occurred (11.6 percent), of which 68 (1.1 percent) and 315 (5.1 percent) were serious adverse events and vomiting, respectively. There was no significant change in the odds ratio of occurrence of any adverse event, serious adverse event, and vomiting with each additional hour of fasting duration for solids and liquids.

"In this study, there was no association between fasting duration and any type of adverse event," the authors write. "These findings do not support delaying sedation to meet established fasting guidelines."

Abstract/Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Moves to Restrict Flavored E-Cig Sales, Ban Menthol Cigarettes

FDA Moves to Restrict Flavored E-Cig Sales, Ban ...

The move stops short of the full ban on e-cigarettes that had been expected

Name-Brand Medications Driving Spike in U.S. Drug Spending

Name-Brand Medications Driving Spike in U.S. Drug Spending

Greatest costs for Humira, Remicade, Enbrel, Novolog, and Neulasta

is free, fast, and customized just for you!




Already a member?

Sign In Now »